Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Monument Tx announce first-in-human clinical study for MT1980, a novel treatment for neuroinflammation, shows drug can access the brain
San Francisco, USA, January 8, 2023: Monument Therapeutics, a stratified neuroscience company, will this week report positive results from their lead clinical program at the Sachs Neuroscience Innovation Forum and Biotech Showcase™ 2023 investor conferences.
In these presentations, Monument Tx will report data from their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound. Healthy volunteers received MT1980 on one occasion at one of three dose levels. Drug was found in the cerebrospinal fluid (CSF) of all the volunteers indicating the presence of the drug in the brain. This novel absorption profile opens the door to leverage novel pharmacology that is not otherwise accessible with the standard on-market formulation of the compound. All the volunteers were well during the study without any significant side effects related to MT1980.
MT1980 has been specifically created as a novel therapy for poorly-treated conditions associated with neuroinflammation, such as Alzheimer’s disease, post-operative cognitive decline and long Covid. In preclinical studies reported in 2022, MT1980 showed excellent brain uptake and strong anti-inflammatory activity.
Monument Therapeutics now plans a further Phase I clinical study to rapidly provide safety and pharmacokinetic data from multiple doses of MT1980, and evidence of an anti-inflammatory effect in the brain.
Kiri Granger, Chief Scientific Officer of Monument Therapeutics, said:
“The success of this first clinical study, proving that an anti-inflammatory can be delivered to the brain without significant side effects, brings us one step closer to the treatment of the many patients experiencing symptoms such as memory loss and cognitive problems as a result of inflammation in the brain. We are excited to continue this work by showing the presence of the drug in the brain creates an anti-inflammatory effect.”
Jenny Barnett, Chief Executive Officer of Monument Therapeutics added:
“We are delighted to announce positive data from Monument Therapeutics’ first clinical study and are already focused on moving rapidly to the next study of MT1980 with the support of our investors and collaborators.”
For further information, contact:
Jenny Barnett, CEO
Notes to Editors:
About Monument Therapeutics
Monument Therapeutics is bringing stratified medicine to CNS drug development. The company uses proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.
For further information visit www.monumenttx.com
